GlassScriptPhysician profile
Jacqueline Surrency
NPI 1568693398
$4,298.51
in general payments reported to CMS, 2019-2025
21 companies · $606 in 2025
The $606 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,534 · 2022: $960 · 2023: $666 · 2024: $533 · 2025: $606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,805.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,116.18 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $744.80 | 2021-2025 | Mounjaro, Trulicity, Zepbound |
| Astrazeneca Pharmaceuticals LP | $670.72 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $323.42 | 2021-2024 | Jardiance, Tradjenta, Synjardy |
| Teva Pharmaceuticals USA, INC. | $235.81 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $162.27 | 2023-2025 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.61 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $122.55 | 2022 | |
| Sanofi-Aventis U.S. LLC | $118.83 | 2021-2022 | |
| Amgen INC. | $111.82 | 2024-2025 | Repatha, Otezla, Repatha |
| Dexcom, INC. | $108.39 | 2021-2023 | Dexcom G6 Transmitter |
| Pfizer INC. | $62.33 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $59.53 | 2021-2022 | |
| Neurelis, INC. | $56.37 | 2021 | |
| Phadia US INC. | $52.34 | 2021-2025 | Immunocap |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $46.19 | 2023 | Amvuttra |
| Astellas Pharma US INC | $45.22 | 2024 | Veozah |
| Vanda Pharmaceuticals INC. | $36.30 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $32.45 | 2023 | Quviviq |
| Mannkind Corporation | $29.69 | 2021 | |
| Si-Bone, INC. | $24.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Surrency listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.